Physicians' Academy for Cardiovascular Education
Healthy food intake was associated with having no coronary artery calcium, and in combination with higher cardiorespiratory fitness, it was also associated with lower CAC levels.
Patients with hypertension with low platelet counts and high total homocysteine levels, which may promote platelet adherence, had the highest risk of first stroke, and this risk was reduced with folic acid treatment.
In a large community-based database, in patients with peripheral artery disease, statin therapy was associated with a significant reduction of amputations and mortality compared with no statin use.
In a double-blind pilot study, a single lean vegan-donor fecal microbiota transplantation in obese male patients with metabolic syndrome did not alter markers of arterial wall inflammation.
Mendelian randomization study suggests that lowering LDL affects large artery atherosclerosis, but not small artery occlusion or cardioembolic stroke, while increasing HDL may benefit small artery disease.
In young asymptomatic individuals with family history of premature ASCVD, elevated Lp(a) is related to higher CAC score, resulting in the identification of individuals with subclinical atherosclerosis.
Evolocumab significantly changes lipoprotein particle number and size, irrespective of concordance with LDL-c at baseline or disease status.
Prof. John Kastelein describes 3 major disturbances in lipoprotein metabolism contributing to CV risk. Novel therapies are being developed to address residual risk after LDL-c eradication.
Dr. Christopher Cannon explains the CV benefits of CETP inhibition in relation to non-HDL-c reduction
Dr. Samia Mora summarizes the challenges in lipid management with respect to testing and treatment.
Several lipid-lowering treatments have been shown to exert CV benefits. Prof. Deepak Bhatt discusses how to integrate PCSK9 inhibitors into these therapies for primary and secondary CV prevention.
Dr. Robert Giugliano summarizes what we have learned over the past decades about the effectiveness and safety of reducing LDL-c to very low values.
